TABLE 2.
Baseline characteristics of the propensity score-matched cohort, stratified by CYP2C19 metabolizer phenotype and treatment group.
| Baseline characteristics | EM type (n = 208) | IM type (n = 226) | PM type (n = 80) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Clop. (n = 104) | Tica. (n = 104) | SMD | Clop. (n = 113) | Tica. (n = 113) | SMD | Clop. (n = 40) | Tica. (n = 40) | SMD | |
| Age (year) | 58.15 ± 10.14 | 60.02 ± 9.31 | 0.191 | 57.63 ± 11.03 | 58.25 ± 10.66 | 0.057 | 58.78 ± 10.65 | 60.15 ± 9.64 | 0.134 |
| Male, n (%) | 54 (51.92%) | 56 (53.85%) | 0.039 | 61 (53.98%) | 57 (50.44%) | 0.071 | 22 (55.00%) | 20 (50.00%) | 0.100 |
| Hypertension, n (%) | 67 (64.42%) | 71 (68.27%) | 0.081 | 69 (61.06%) | 71 (62.83%) | 0.036 | 26 (65.00%) | 25 (62.50%) | 0.052 |
| Diabetes, n (%) | 49 (47.12%) | 54 (51.92%) | 0.096 | 45 (39.82%) | 50 (44.25%) | 0.090 | 17 (42.50%) | 15 (37.50%) | 0.102 |
| Smoking, n (%) | 41 (39.42%) | 39 (37.50%) | 0.040 | 51 (45.13%) | 48 (42.48%) | 0.054 | 20 (50.00%) | 18 (45.00%) | 0.100 |
| NIHSS score (x ± s) | 3.32 ± 1.43 | 3.17 ± 1.64 | 0.097 | 3.41 ± 1.31 | 3.24 ± 1.64 | 0.114 | 3.25 ± 1.52 | 3.05 ± 1.72 | 0.122 |
| LDL-C, mmol/L | 3.71 ± 1.41 | 3.84 ± 1.47 | 0.090 | 3.91 ± 1.51 | 4.05 ± 1.44 | 0.095 | 3.71 ± 1.38 | 3.90 ± 1.52 | 0.130 |
Data are presented as mean ± standard deviation or number. NIHSS, national institutes of health stroke scale; LDL-C, low-density lipoprotein cholesterol. There were no significant differences in all baseline characteristics between the clopidogrel and ticagrelor groups within any metabolizer group (all P > 0.05).